

Supplemental Material

Table S1. Baseline characteristics at the index infarction of patients with first-occurrence myocardial infarction with culprit lesion identified and indeterminate recurrent myocardial infarction during follow-up.

Variable (n, %)	First-occurrence myocardial infarction with culprit artery identified (n = 44 332)	Recurrent myocardial infarction, indeterminate (n = 1566)
Men	31 155 (70.3)	930 (59.4)
Age (years)	66 ± 11.70	71.3 ± 11.8
Body weight (kg)	81.3 ± 15.7	78.5 ± 15.9
Indication for the coronary angiography during hospitalization for the index myocardial infarction		
ST-elevation MI	23 446 (53)	735 (47.3)
Non-ST-elevation MI	20 752 (47)	820 (52.7)
Coexisting conditions		
Hypertension	18 494 (42.1)	825 (53.2)
Diabetes mellitus	6314 (14.3)	385 (24.6)
Statin use at admission	7216 (16.4)	380 (24.5)
Smoker status: current	12 706 (29.2)	363 (23.6)
Smoker status: former >1 month	18 899 (32.3)	510 (33.1)
Previous MI	0 (0)	0 (0)
Previous PCI	1678 (2.6)	101 (6.5)
Previous stroke	5891 (9.5)	145 (9.7)
Angiographic findings during hospitalization for the index myocardial infarction		
One-vessel disease (not LM)	26 912 (60.8)	705 (45.1)
Two-vessel disease (not LM)	10 592 (23.9)	407 (26.1)

Three-vessel disease (not LM)	5145 (11.6)	318 (20.4)
Left main stem	1227 (2.8)	119 (7.6)
PCI at the during hospitalization for the index myocardial infarction		
No. of stents per procedure	1.1 ± 0.6	1.1 ± 0.6
Drug-eluting stent	17 947 (43.9)	411 (30.4)
Bare-metal stent	23 115 (56.7)	951 (70.7)
Stent diameter, mean (mm)	3.1 ± 0.5	3.0 ± 0.5
Total stent length, mean (mm)	21.5 ± 10.8	21.1 ± 10.3
Treated vessel: RCA	14 696 (33.1)	477 (30.5)
Treated vessel: Left main	493 (1.1)	27 (1.7)
Treated vessel: LAD	19 856 (44.8)	700 (44.7)
Treated vessel: LCX	9996 (22.5)	359 (22.9)
ASA	7996 (18.2)	501 (32.3)
Clopidogrel	863 (2.0)	64 (4.1)
Ticagrelor	63 (0.1)	2 (0.1)
Prasugrel	4 (0.4)	0 (0)
Medications during PCI for the index myocardial infarction		
GP IIb/IIIa	10 328 (23.3)	360 (23.0)
Heparin	30 461 (68.7)	1045 (66.7)
LMWH	1765 (4.0)	76 (4.9)
Bivalirudin	15 935 (36.0)	460 (29.4)
Medications at discharge for the index myocardial infarction		
ASA	42 264 (95.8)	501 (32.3)

Clopidogrel	30 803 (69.6)	64 (4.1)
Ticagrelor	10 412 (23.5)	2 (0.1)
Prasugrel	1076 (2.4)	0 (0)
Beta blockers	40 046 (90.5)	1409 (90.1)
ACE/AT II inhibitors	34 901 (78.9)	1242 (79.4)
Calcium antagonists	4910 (11.1)	273 (17.5)
Warfarin	2176 (4.9)	93 (6.0)
Statins	41787 (94.5)	1448 (92.6)

ASA, acetylsalicylic acid; CABG, coronary artery bypass grafting; GP, glycoprotein; LAD, left anterior descending artery; LCX, left circumflex artery; LM, left main stem; LMWH, low-molecular-weight heparin; MI, myocardial infarction; PCI, percutaneous coronary intervention; RCA, right coronary artery.

Table S2. Angiographic findings in the subgroup of patients with identified culprit lesion at the index infarction and indeterminate recurrent myocardial infarction undergoing coronary catheterization.

Variable (n, %)	Recurrent myocardial infarction, indeterminate (n = 661)
Angiographic findings at the recurrent MI	
No stenosed vessels	288 (43.7)
One-vessel disease (not LM)	145 (22.0)
Two-vessel disease (not LM)	100 (15.2)
Three-vessel disease (not LM)	68 (10.3)
Main stem	58 (8.8)
Lesion severity:	
A	28 (31.5)
B1	37 (41.6)
B2	11 (12.4)
C	8 (9.0)
Definitive stent thrombosis	0 (0)

LM, left main stem.

Figure S1. Cumulative event probability estimated by the Kaplan–Meier method and numbers of patients at risk of recurrent myocardial infarction in patients with (yes) and without (no) the culprit lesion identified for the index myocardial infarction.

